Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | CHIEF FINANCIAL OFFICER | September 17, 2026 | September 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enliven Therapeutics, Inc.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,000 |
Last balance in matching sequence
After 2026-09-17 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2026-09-17 · Exercise / conversion · Acquired 3,982 · Balance 44,018 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Row 2 · 2026-09-17 · Sale · Disposed 3,535 · Balance 40,483 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F3: This transaction was executed in multiple trades at prices ranging from $49.31 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Row 3 · 2026-09-17 · Sale · Disposed 2,194 · Balance 38,289 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F4: This transaction was executed in multiple trades at prices ranging from $50.31 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Row 4 · 2026-09-17 · Sale · Disposed 289 · Balance 38,000 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F5: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.85 · Expires 2034-02-13 | Direct | 181,018 |
Reported balance
After 2026-09-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-17 · Exercise / conversion · Disposed 3,982 · Balance 181,018 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F6: The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3: This transaction was executed in multiple trades at prices ranging from $49.31 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4: This transaction was executed in multiple trades at prices ranging from $50.31 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6: The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2024 Filed Oct 1, 2024 23:53 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-024249 · form4-10012024_111017.xml · derivative · entry 6 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,879 Underlying: Common Stock · 2,000 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 23:53 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,000 | $25.33 | $50,667.60 |
DisclosureSEC source: 0001415889-24-024249 · form4-10012024_111017.xml · nonDerivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $25.12 to $25.535. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 23:53 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 2,000 | $2.48 | $4,960.00 |
DisclosureSEC source: 0001415889-24-024249 · form4-10012024_111017.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 23:53 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 4,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-024249 · form4-10012024_111017.xml · derivative · entry 5 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,879 Underlying: Common Stock · 4,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 23:53 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 4,250 | $24.27 | $103,161.10 |
DisclosureSEC source: 0001415889-24-024249 · form4-10012024_111017.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.085 to $24.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 23:53 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 4,250 | $2.48 | $10,540.00 |
DisclosureSEC source: 0001415889-24-024249 · form4-10012024_111017.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 22:36 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 4,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-022589 · form4-08292024_100833.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 199,129 Underlying: Common Stock · 4,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 22:36 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 4,250 | $22.54 | $95,781.83 |
DisclosureSEC source: 0001415889-24-022589 · form4-08292024_100833.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.02 to $22.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 22:36 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 4,250 | $2.48 | $10,540.00 |
DisclosureSEC source: 0001415889-24-022589 · form4-08292024_100833.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 23:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 991 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-020686 · form4-08022024_110825.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,379 Underlying: Common Stock · 991 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 23:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 991 | $27.53 | $27,280.94 |
DisclosureSEC source: 0001415889-24-020686 · form4-08022024_110825.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $27.655. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 23:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 991 | $2.48 | $2,457.68 |
DisclosureSEC source: 0001415889-24-020686 · form4-08022024_110825.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 23:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-020475 · form4-07312024_110716.xml · derivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,370 Underlying: Common Stock · 5,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 23:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 61 | $27.44 | $1,674.03 |
DisclosureSEC source: 0001415889-24-020475 · form4-07312024_110716.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $27.41 to $27.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 23:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 5,189 | $26.67 | $138,378.18 |
DisclosureSEC source: 0001415889-24-020475 · form4-07312024_110716.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.34 to $27.3359. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 23:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 5,250 | $2.48 | $13,020.00 |
DisclosureSEC source: 0001415889-24-020475 · form4-07312024_110716.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 21:34 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-019598 · form4-07162024_090739.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,620 Underlying: Common Stock · 3,000 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 21:34 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,000 | $25.07 | $75,195.00 |
DisclosureSEC source: 0001415889-24-019598 · form4-07162024_090739.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.19. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 21:34 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,000 | $2.48 | $7,440.00 |
DisclosureSEC source: 0001415889-24-019598 · form4-07162024_090739.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| June 27, 2024 Filed Jul 2, 2024 00:03 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 4,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-018694 · form4-07022024_120743.xml · derivative · entry 5 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,620 Underlying: Common Stock · 4,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F5 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 27, 2024 Filed Jul 2, 2024 00:03 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,140 | $23.43 | $26,711.11 |
DisclosureSEC source: 0001415889-24-018694 · form4-07022024_120743.xml · nonDerivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $23.37 to $23.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 27, 2024 Filed Jul 2, 2024 00:03 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,830 | $22.58 | $41,313.35 |
DisclosureSEC source: 0001415889-24-018694 · form4-07022024_120743.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,140 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $22.2058 to $23.1325. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 27, 2024 Filed Jul 2, 2024 00:03 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,280 | $21.79 | $27,897.09 |
DisclosureSEC source: 0001415889-24-018694 · form4-07022024_120743.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,970 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.145 to $22.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 27, 2024 Filed Jul 2, 2024 00:03 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 4,250 | $2.48 | $10,540.00 |
DisclosureSEC source: 0001415889-24-018694 · form4-07022024_120743.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:54 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 4,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-014914 · form4-05302024_090558.xml · derivative · entry 5 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,870 Underlying: Common Stock · 4,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:54 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 10 | $24.34 | $243.40 |
DisclosureSEC source: 0001415889-24-014914 · form4-05302024_090558.xml · nonDerivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:54 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,334 | $23.42 | $54,658.55 |
DisclosureSEC source: 0001415889-24-014914 · form4-05302024_090558.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $23.28 to $23.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:54 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,906 | $22.89 | $43,628.34 |
DisclosureSEC source: 0001415889-24-014914 · form4-05302024_090558.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,344 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.275 to $23.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:54 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 4,250 | $2.48 | $10,540.00 |
DisclosureSEC source: 0001415889-24-014914 · form4-05302024_090558.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| May 03, 2024 Filed May 7, 2024 22:58 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-012536 · form4-05072024_100528.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,120 Underlying: Common Stock · 1,000 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 03, 2024 Filed May 7, 2024 22:58 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,000 | $22.50 | $22,500.00 |
DisclosureSEC source: 0001415889-24-012536 · form4-05072024_100528.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| May 03, 2024 Filed May 7, 2024 22:58 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 1,000 | $2.48 | $2,480.00 |
DisclosureSEC source: 0001415889-24-012536 · form4-05072024_100528.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| April 29, 2024 Filed May 1, 2024 23:02 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-011914 · form4-05012024_110511.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 222,120 Underlying: Common Stock · 3,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| April 29, 2024 Filed May 1, 2024 23:02 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,250 | $16.97 | $55,164.53 |
DisclosureSEC source: 0001415889-24-011914 · form4-05012024_110511.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.56 to $17.41. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 29, 2024 Filed May 1, 2024 23:02 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,250 | $2.48 | $8,060.00 |
DisclosureSEC source: 0001415889-24-011914 · form4-05012024_110511.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 23:04 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-010827 · form4-04152024_110419.xml · derivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 225,370 Underlying: Common Stock · 14,000 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 23:04 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 10,223 | $25.04 | $255,969.61 |
DisclosureSEC source: 0001415889-24-010827 · form4-04152024_110419.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $24.69 to $25.51. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 23:04 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,777 | $23.88 | $90,179.27 |
DisclosureSEC source: 0001415889-24-010827 · form4-04152024_110419.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,223 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.65 to $24.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 23:04 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 14,000 | $2.48 | $34,720.00 |
DisclosureSEC source: 0001415889-24-010827 · form4-04152024_110419.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 21:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-009450 · form4-03292024_090320.xml · derivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 239,370 Underlying: Common Stock · 3,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 21:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 182 | $18.72 | $3,406.79 |
DisclosureSEC source: 0001415889-24-009450 · form4-03292024_090320.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $18.69 to $18.755. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 21:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,068 | $18.22 | $55,895.59 |
DisclosureSEC source: 0001415889-24-009450 · form4-03292024_090320.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.69 to $18.66. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 21:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,250 | $2.48 | $8,060.00 |
DisclosureSEC source: 0001415889-24-009450 · form4-03292024_090320.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:27 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-005930 · form4-02292024_100247.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 242,620 Underlying: Common Stock · 3,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:27 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,250 | $16.97 | $55,162.90 |
DisclosureSEC source: 0001415889-24-005930 · form4-02292024_100247.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.60 to $17.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:27 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,250 | $2.48 | $8,060.00 |
DisclosureSEC source: 0001415889-24-005930 · form4-02292024_100247.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 01:54 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 185,000 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001415889-24-004020 · form4-02162024_010205.xml · derivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2034-02-12 F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 13, 2025 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 29, 2024 Filed Feb 1, 2024 02:20 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-002125 · form4-02012024_020258.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 245,870 Underlying: Common Stock · 3,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 29, 2024 Filed Feb 1, 2024 02:20 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,250 | $15.81 | $51,388.35 |
DisclosureSEC source: 0001415889-24-002125 · form4-02012024_020258.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.58 to $16.295. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 29, 2024 Filed Feb 1, 2024 02:20 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,250 | $2.48 | $8,060.00 |
DisclosureSEC source: 0001415889-24-002125 · form4-02012024_020258.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.